文献速递白血病造血干细胞移植与细胞治疗

维奈克拉联合FLAG-IDA方案诱导和巩固治疗初诊及复发难治急性髓系白血病

Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia.
PubMed 文献 · J Clin Oncol · 2021-05-27

这项Ib/II期研究评估了氟达拉滨、阿糖胞苷、粒细胞集落刺激因子、伊达比星联合B细胞淋巴瘤-2抑制剂维奈克拉在初诊和复发难治急性髓系白血病中的安全性和疗效。初诊组可测量残留病阴性复合完全缓解率达96%,复发难治组为69%。

要点

  • FLAG-IDA联合维奈克拉在初诊AML中复合完全缓解率达90%,可测量残留病阴性率96%。
  • 复发难治AML中总缓解率70%,复合完全缓解率61%,可测量残留病阴性率69%。

核心结论

  • 氟达拉滨、阿糖胞苷、粒细胞集落刺激因子、伊达比星联合维奈克拉是初诊和复发难治急性髓系白血病的有效强化治疗方案,可获得深度缓解并高比例桥接移植。

研究设计与样本

  • Ib/II期研究,Ib期采用3+3剂量递增和递减算法确定最大耐受剂量和剂量限制性毒性,II期分IIA组(初诊AML)和IIB组(复发难治AML)评估缓解和事件时间终点。

主要发现

  • Ib期、IIA组、IIB组总缓解率分别为75%、97%、70%,复合完全缓解率分别为75%、90%、61%。
  • 初诊AML可测量残留病阴性复合完全缓解率96%,复发难治AML为69%。
  • 中位随访12个月,两个II期队列的中位总生存均未达到。
  • 复发难治AML中,异基因造血干细胞移植显著改善总生存(中位总生存未达到;1年总生存率87%);移植后1年生存率初诊AML为94%、复发难治AML为78%。

关键数值与推荐

  • ≥10%患者发生的3级和4级不良事件包括发热性中性粒细胞减少(50%)、菌血症(35%)、肺炎(28%)和脓毒症(12%)。

临床怎么用

  • 该强化方案可用于初诊和复发难治急性髓系白血病,以深度缓解和桥接异基因造血干细胞移植为目标。
  • 治疗期间需重点监测发热性中性粒细胞减少、菌血症、肺炎和脓毒症等感染性不良事件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Sixty percent of newly diagnosed patients with acute myeloid leukemia (ND-AML) receiving frontline therapy attain a complete response (CR), yet 30%-40% of patients relapse. Relapsed or refractory AML (R/R-AML) remains a particularly adverse population necessitating improved therapeutic options. This phase Ib/II study evaluated the safety and efficacy of fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin combined with the B-cell lymphoma-2 inhibitor venetoclax in ND-AML and R/R-AML. MATERIALS AND METHODS: The phase IB portion (PIB) enrolled patients with R/R-AML using a 3 + 3 dose escalation and de-escalation algorithm for identification of maximum tolerated dose and dose-limiting toxicities. The phase II portion enrolled patients into two arms to evaluate response and time-to-event end points: phase IIA (PIIA): ND-AML and phase IIB (PIIB): R/R-AML. RESULTS: Sixty-eight patients have enrolled to date (PIB, 16; PIIA, 29; PIIB, 23). Median age was 46 years (range, 20-73). Grade 3 and 4 adverse events occurring in ≥ 10% of patients included febrile neutropenia (50%), bacteremia (35%), pneumonia (28%), and sepsis (12%). The overall response rate for PIB, PIIA, and PIIB was 75%, 97%, and 70% with 75%, 90%, and 61%, respectively, achieving a composite CR. Measurable residual disease-negative composite CR was attained in 96% of ND-AML and 69% of R/R-AML patients. After a median follow-up of 12 months, median overall survival (OS) for both PII cohorts was not reached. Fifty-six percent of patients proceeded to allogeneic hematopoietic stem-cell transplantation (ND-AML, 69%; R/R-AML, 46%). In R/R-AML, allogeneic hematopoietic stem-cell transplantation resulted in a significant improvement in OS (median OS, NR; 1-year OS, 87%). One-year survival post-HSCT was 94% in ND-AML and 78% in R/R-AML. CONCLUSION: Fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin + venetoclax represents an effective intensive treatment regimen in ND-AML and R/R-AML patients, associated with deep remissions and a high rate of transition to successful transplantation.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. DiNardo CD, Lachowiez CA, Takahashi K, et al. Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia. J Clin Oncol. 2021. PMID: 34043428. doi:10.1200/JCO.20.03736

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。